Clinical Trials Browser

Recurrence × sintilimab × 90 days × Clear all

NCT07581821 2026-05-12

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence